A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia

Completed · Phase 3

Conditions studied: Hypercholesterolemia, Dyslipidemia

In brief

The purpose of this study is to evaluate the safety and efficacy of ABT-335 and rosuvastatin calcium combination therapy to monotherapy in subjects with dyslipidemia.

Key facts

Study ID

NCT00463606

Run by

AstraZeneca

People needed

760

Starts

2007-04-01

Expected to finish

2008-02-01

Last updated by the study team

2012-10-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult male and female participants who voluntarily sign the informed consent.
• Fasting lipid results following greater than 12-hour fasting period:
• Triglycerides level greater than or equal to 150 mg/dL,
• High-density lipoprotein cholesterol less than 40 mg/dL for males and less than 50 mg/dL for females, and
• Low-density lipoprotein cholesterol greater than or equal to 130 mg/dL.
• Participant must agree to utilize adequate birth control methods and adhere to the American Heart Association (AHA) diet.

You may not qualify if…

• Participants with unstable medical conditions, medical conditions considered inappropriate in a clinical trial, or participants who are taking excluded concomitant medications are not allowed in the study.
• Participants receiving coumarin anticoagulants or systemic cyclosporine.

Where it is running

• Site Reference ID/Investigator# 4428 — Birmingham, Alabama, United States
• Site Reference ID/Investigator# 4985 — Birmingham, Alabama, United States
• Site Reference ID/Investigator# 4493 — Huntsville, Alabama, United States
• Site Reference ID/Investigator# 4510 — Huntsville, Alabama, United States
• Site Reference ID/Investigator# 4431 — Ozark, Alabama, United States
• Site Reference ID/Investigator# 4519 — Tuscaloosa, Alabama, United States
• Site Reference ID/Investigator# 4395 — Chandler, Arizona, United States
• Site Reference ID/Investigator# 4483 — Gilbert, Arizona, United States
• Site Reference ID/Investigator# 4411 — Scottsdale, Arizona, United States
• Site Reference ID/Investigator# 4417 — Little Rock, Arkansas, United States
• Site Reference ID/Investigator# 4702 — Anaheim, California, United States
• Site Reference ID/Investigator# 5593 — Chula Vista, California, United States
• Site Reference ID/Investigator# 4503 — Concord, California, United States
• Site Reference ID/Investigator# 4530 — Encinitas, California, United States
• Site Reference ID/Investigator# 4458 — Fair Oaks, California, United States
• Site Reference ID/Investigator# 4542 — Fresno, California, United States
• Site Reference ID/Investigator# 4574 — Fresno, California, United States
• Site Reference ID/Investigator# 4441 — Lincoln, California, United States
• Site Reference ID/Investigator# 4432 — Long Beach, California, United States
• Site Reference ID/Investigator# 5579 — Los Angeles, California, United States
• Site Reference ID/Investigator# 4980 — Norwalk, California, United States
• Site Reference ID/Investigator# 4392 — Sacramento, California, United States
• Site Reference ID/Investigator# 4896 — Sacramento, California, United States
• Site Reference ID/Investigator# 5582 — San Diego, California, United States
• Site Reference ID/Investigator# 5469 — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.